Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102).

被引：0

作者：

Coleman, Morton

Salar, Antonio

Munoz, Javier

Galanina, Natalie

Faivre, Thea

Zinzani, Pier Luigi

机构：

[1] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[2] Hosp del Mar, Barcelona, Spain

[3] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[4] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA

[5] Incyte Corp, Wilmington, DE USA

[6] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS7578

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7578

引用

页数：6